Fortress Biotech (FBIO) Reaches $3.81 After 8.00% Up Move; Idexx Laboratories (IDXX) Shorts Down By 16.5%

November 14, 2017 - By Kurt Siggers

Idexx Laboratories Incorporated (NASDAQ:IDXX) had a decrease of 16.5% in short interest. IDXX’s SI was 1.75M shares in November as released by FINRA. Its down 16.5% from 2.10 million shares previously. With 426,800 avg volume, 4 days are for Idexx Laboratories Incorporated (NASDAQ:IDXX)’s short sellers to cover IDXX’s short positions. The SI to Idexx Laboratories Incorporated’s float is 2.01%. About 434,827 shares traded. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 83.30% since November 14, 2016 and is uptrending. It has outperformed by 66.60% the S&P500.

The stock of Fortress Biotech Inc (NASDAQ:FBIO) is a huge mover today! About 67,138 shares traded. Fortress Biotech Inc (NASDAQ:FBIO) has risen 52.16% since November 14, 2016 and is uptrending. It has outperformed by 35.46% the S&P500.The move comes after 9 months positive chart setup for the $193.00 million company. It was reported on Nov, 14 by Barchart.com. We have $4.11 PT which if reached, will make NASDAQ:FBIO worth $15.44M more.

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The company has market cap of $193.00 million. The Firm is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. It currently has negative earnings. The Company’s sole product candidate is CNDO-109.

Among 2 analysts covering Fortress Biotech (NASDAQ:FBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech has $11 highest and $11.0 lowest target. $11’s average target is 188.71% above currents $3.81 stock price. Fortress Biotech had 4 analyst reports since July 11, 2017 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Tuesday, July 11. As per Thursday, August 10, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Wednesday, September 27.

Analysts await Fortress Biotech Inc (NASDAQ:FBIO) to report earnings on March, 15. They expect $-0.46 EPS, down 6.98% or $0.03 from last year’s $-0.43 per share. After $-0.67 actual EPS reported by Fortress Biotech Inc for the previous quarter, Wall Street now forecasts -31.34% EPS growth.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The company has market cap of $13.00 billion. The Firm also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. It has a 48.34 P/E ratio. The Company’s divisions include diagnostic and information technology services and products for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic services and products for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements.

Since May 22, 2017, it had 0 insider buys, and 2 sales for $1.24 million activity. Shares for $429,272 were sold by TWIGGE GIOVANI on Wednesday, May 31. The insider END WILLIAM T sold 5,000 shares worth $812,769.

Among 9 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 5 have Buy rating, 2 Sell and 2 Hold. Therefore 56% are positive. IDEXX Laboratories had 22 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, July 24 by Feltl & Co. The stock has “Outperform” rating by Credit Suisse on Wednesday, April 13. On Thursday, February 4 the stock rating was initiated by Credit Suisse with “Outperform”. The firm has “Buy” rating by Bank of America given on Wednesday, August 23. The stock has “Buy” rating by Canaccord Genuity on Monday, August 21. Stifel Nicolaus maintained it with “Buy” rating and $80 target in Thursday, October 29 report. Stifel Nicolaus maintained it with “Buy” rating and $85 target in Monday, March 21 report. The rating was downgraded by Raymond James on Friday, August 28 to “Market Perform”. Canaccord Genuity maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) rating on Wednesday, July 20. Canaccord Genuity has “Buy” rating and $98 target. Canaccord Genuity maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) rating on Thursday, July 23. Canaccord Genuity has “Buy” rating and $75 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com